Table 4.
Reactivity of L612 HuMAb to melanoma, carcinoma, and normal tissues. IH immunohistochemistry, IA immune adherence, MIF membrane immunofluorescence, PBL peripheral blood lymphocytes
| Biopsied, surgical, and autopsied tissues | Type of assay (L612 HuMAb dose) | No. positive/no. tested |
|---|---|---|
| Melanoma | IA (10 μg/ml) | 63/86 (73.3%)b |
| Melanoma | MIF (100 μg/ml) | 54/82 (65.9%)c |
| Melanoma | Direct IH (20 μg/ml) | 13/20 (65%) |
| Colon cancer | Direct IH (20 μg/ml) | 4/5 (80%) |
| Ovarian cancer | Direct IH (20 μg/ml) | 4/5 (80%) |
| Pancreas cancer | Direct IH (20 μg/ml) | 3/5 (60%) |
| Prostate cancer | Direct IH (20 μg/ml) | 2/5 (40%) |
| Breast cancer | Direct IH (20 μg/ml) | 2/5 (40%) |
| Kidney cancer | Direct IH (20 μg/ml) | 2/5 (40%) |
| Lung cancer | Direct IH (20 μg/ml) | 0/5 (0%) |
| Normal tissuesa | Direct IH (20 μg/ml) | 0/62 (0%) |
| Erythrocytes | IA absorption (100 μg/ml) | 0/44 (0%)d |
| PBL | IA absorption (100 μg/ml) | 0/32 (0%)d |
aSixty-two normal human tissues were obtained from 24 different organ sites: cerebellum (3), cerebrum (1), pons (2), spinal cord (2), eye (3), skin (2), muscle (3), breast (2), salivary glands (2), larynx (4), esophagus (4), stomach (2), duodenum (4), colon (2), liver (4), lung (2), heart (4), thyroid (4), spleen (2), lymph nodes (2), bladder (2), kidney (2), ovaries (2), and testis (2)
bPositive specimens were those with an IA score >2. Of the 86 specimens, 81 (94.2%) had an IA score >1 (data not shown)
cPositive specimens were those with an MIF score >25%. Of the 82 specimens, 76 (92.8%) had an MIF score >10% (data not shown)
dPreviously reported elsewhere [4]